Italia markets closed

Stryker Corporation (SYK)

NYSE - NYSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
270,94+1,76 (+0,65%)
Alla chiusura: 4:05PM EDT
Accedi per pubblicare un messaggio.
  • M
    Michael
    $SRGA conversation
    According to Factset Research, $SYK spine business beat expectations by 8% generating $307 million in revenue compared to expectations of $283 million.

    Overall, $SYK beat revenue expectations by about 3% at $4.3 billion.

    SYK’s spine business appears most comparable to $SRGA which is a pure play spine company.

    SRGA reports on Aug. 6
  • s
    stocktargetadvisor
    $SYK conversation
    $SYK
    Upgrades Evercore ISI Outperform USD 260 » USD 285
  • M
    MarketMania
    $MESO conversation
    To All New MESO shareholders and stem cell / MESO naysayers – a lot of us long-time shareholders (Minnesota, Left-e, Seanpierre1, Josephine, Frank/ Tarentella 123, Francesca, George, etc..) have been involved with Osiris for a very long time – some as early as the IPO, and others that have bought over the years. I first bought Osiris in 2011 after a lot of research and continued to buy over a period of years. When Osiris partnered with Mesoblast in October 2013, it was a huge disappointment in my mind – but in hindsight, is was a great decision by Peter Friedli. Peter knew that taking Prochymal – Remestemcel-L to market would have required a lot of capital/dilution. This enabled Osiris to focus on Grafix, GrafixPL, Stravix, etc. Peter was excellent at choosing the right partner for Osiris’ technology/science. NuVasive, Inc. $NUVA for Osteocel, Stryker Corporation $SYK for BIO4, Arthrex for BIO4, etc. until Smith & Nephew $SNN bought our Osiris in March of 2019. Peter was a co-founder of the Osiris along with Kevin Kimberlin. I would suggest EVERYONE search Kevin’s website – first and last name together dot com – to understand his background. I know some long term shareholders who had the opportunity to meet Kevin in the past at Osiris’ shareholders meetings. He is a very intelligent individual and his background is VERY IMPRESSIVE. The SCIENCE is ready for PRIME TIME. Anyone looking at the small sample size of the Covid-19 trial – need to look at the past trials and the success to draw any conclusions. Many of us have had the opportunity to tour Osiris’ headquarters in Maryland – their walls were lined with children that were saved by their SCIENCE. That was their motivation! Peter knew when to partner with the right company. We’ll see when/if MESO will partner with big pharma – hopefully it’s north of $75/share. Until then, do your own research and understand the science/history. We’re at a critical stage of stem cell therapies and MESO is the BEST horse in the race. Disclaimer: long a lot of $ATHX too! …. And the $MDXG Cheerleaders deserve a shout out to – you shouldn’t have drank Pete’s Kool-Aid and listened to Beef, Peter, Wendy, Frozen, BrianX, Homebuilder, etc. – they’re all clueless and people that follow them - continue to miss a great opportunity!
  • T
    Techfan20
    $OSIR conversation
    Grafix (wound product) is currently pulling the $OSIR train, yet BIO4 holds huge potential in bone market.
    BIO4 revenue is growing consistently and at an accelerating pace (compared the same quarter year earlier):
    Q3 2017 21%
    Q4 2017 23%
    Q1 2018 27%
    Q2 2018 54%
    BIO4 is distributed by $SYK, keep up the good work!
  • S
    StockStuffer
    $ASYS conversation
    The robotic surgery market includes
    $MDT market cap 158B
    $ISRG market cap 94B
    $SYK market cap 91B
    $ZBH market cap 34B
    $EDAP
    A lesser known play that uses high frequency ultrasound to target cancer without the incision is EDAP if you want to broaden the portfolio. The robotics guides the waves and essentially burns the cancer cells killing them and the body takes care of the rest.
  • J
    John
    $AAL conversation
    $AAPL & $SYK to carry market tomorrow.
  • e
    eric g
    Why would the shares be down this much when SYK killed it in Q2 Quarterly Earnings?
  • A
    Anonymous
    $SYK conversation
    $SYK
    Maintains Morgan Stanley Overweight USD 272 » USD 265 2021-01-28
    Target Raised by Deutsche Bank Buy USD 228 » USD 25
    Target Raised by Raymond James Financial Outperform USD 240 » USD 255
    Target Lowered by Credit Suisse Outperform » Outperform USD 278 » USD 273
  • B
    Biotechbonanza
    $SYK conversation
    With Trump in office a couple of big catalysts coming for SYK-repatriation of their $3 Billion in cash sitting overseas and removal of the 2.3% medical device tax, which affects SYK the most out of every other stock in the sector.
  • S
    Stockguru
    $SYK conversation
    why is this stock being sold off? Thinking of adding here!
  • M
    MarkyP
    $SYK conversation
    SYK down 12% in 4 days. Good news today of deal with Indian healthcare company that provides health services to 400 Million Indians. Good opportunity to buy a sector leader and solid growth stock.
  • T
    Trent
    $SYK conversation
    Read the interesting report $SYK
    http://bit.ly/2elzLjc
  • L
    LHH
    $SYK conversation
    stock down maybe because of this....Stryker Corp. logoStryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, November 21st. The stock was sold at an average price of $112.01, for a total value of $672,060.00. Following the sale, the director now owns 193,142 shares of the company’s stock, valued at approximately $21,633,835.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
  • C
    Cisco
    $SYK conversation
    Anyone know why this is going down? Like to get in if makes sense. Doesn't seem like insider sellng is the reason
  • P
    Preston
    $SYK conversation
    Removal of tax almost certain but maybe not entirely priced in? Like to see that bump us up to 140 or so then maybe a split? Don't know the current boards thoughts on that but it's time!
  • N
    Nick
    $SYK conversation
    We are really having some challenges breaking out of the 115-120 area.
  • C
    Cisco
    $SYK conversation
    Will SYK ever go back to the $120 level? why this fall ?? or like they say "Never try to catch a falling knife"..
  • N
    Nick
    $SYK conversation
    They sold 30 MAKO in the 1/4. That is huge good news that brings with it recurring revenue. I'm in.
  • D
    David
    $BSX conversation
    Frederick L. Weiss, CFA, is a Senior Investment Manager and leads the research efforts of CIBC Private Wealth Management’s investment team. Mr. Weiss is also co-manager of the firm’s Mid-Cap Growth Equity Strategy, where he is responsible for researc
    Frederick L. Weiss, CFA, is a Senior Investment Manager and leads the research efforts of CIBC Private Wealth Management’s investment team. Mr. Weiss is also co-manager of the firm’s Mid-Cap Growth Equity Strategy, where he is responsible for researc
    www.twst.com
  • N
    Nick
    $SYK conversation
    Ok so what the heck did I miss. I can't find the news section for SYK.....where did we lose 5 point last night? Anybody ?